Xin Wang

Dr. Xin Wang

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
XWXun Wang
Xun Wang
XWXin Wang
Xin Wang
BHBengang Hui
Bengang Hui
JCJingsheng Cai
Jingsheng Cai
HZHeng Zhao
Heng Zhao
FYFan Yang
Fan Yang
Background: Resectable non-small cell lung cancer (NSCLC) patients have a high risk of recurrence. Multiple randomized controlled trials (RCTs) have shown that neoadjuvant chemo-immunotherapy brings new hope for these patients. The study aims to evaluate the safety, surgery-related outcomes and oncological outcomes for neoadjuvant chemo-immunotherapy in real-world setting with a large sample size and long-term follow-up. Methods: Patients with clinical stage IB–IIIB NSCLC who received neoadjuvant chemo-immunotherapy at two Chinese institutions were included in this retrospective cohort study. Surgical and oncological outcomes of the enrolled NSCLC patients were collected and analyzed. Results: There were 158 patients identified, of which 124 (78.5%) were at stage IIIA–IIIB and the remaining 34 (21.5%) were at stage IB–IIB. Forty-one patients (25.9%) received two cycles of neoadjuvant treatment, 80 (50.6%) had three cycles, and 37 (23.4%) had four cycles. Twenty-four patients (15.2%) experienced grade 3 or worse immune-related adverse events. The median interval time between the last neoadjuvant therapy and surgery was 37 [interquartile range (IQR), 31–43] days. Fifty-eight out of 96 (60.4%) central NSCLC patients who were expected to undergo complex surgery had the scope or the difficulty of operation reduced. Ninety-five (60.1%) patients achieved major pathologic response (MPR), including 62 (39.2%) patients with pathologic complete response (pCR). Multivariate regression analysis showed that no clinical factor other than programmed death-ligand 1 (PD-L1) expression was predictive of the pathological response. The median follow-up time from diagnosis was 27.1 months. MPR and pCR were significantly associated with improved progression-free survival (PFS) and overall survival (OS). Neither stage nor PD-L1 expression was significantly associated with long-term survival. Conclusions: The neoadjuvant chemo-immunotherapy is a feasible strategy for NSCLC with a favorable rate of pCR/MPR, modified resection and 2-year survival. No clinical factor other than PD-L1 expression was predictive of the pathological response. pCR/MPR may be effective surrogate endpoint for survival in NSCLC patients who received neoadjuvant chemo-immunotherapy.

15 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Yanbo WangYanbo Wang
Yanbo Wang
WZWeiran Zhang
Weiran Zhang
XWXin Wang
Xin Wang
HZHan Zhang
Han Zhang
QMQingqing Ma
Qingqing Ma
DSDaqiang Sun
Daqiang Sun
Background: Neoadjuvant immunochemotherapy improves pathological response in resectable non-small cell lung cancer (NSCLC), but the need and intensity of postoperative adjuvant therapy across different pathological response rate (PRR) strata remain uncertain. Methods: In this single-center retrospective cohort, 105 patients with resectable NSCLC received neoadjuvant platinum-based chemotherapy with or without PD-1/PD-L1 inhibitors followed by R0 resection. PRR was defined as 1—residual viable tumor fraction and categorized as 0–60%, 60–90%, and ≥90% (major pathological response, MPR). Postoperative strategies included no further therapy, chemotherapy alone, or immunotherapy ± chemotherapy. Event-free survival (EFS) was analyzed using Kaplan–Meier estimates, multivariable Cox models, and restricted cubic spline-based treatment × PRR interaction. Results: Deeper PRR was associated with lower ypT/ypN stage and improved EFS. In the PRR 0–60% subgroup, immunotherapy-containing adjuvant regimens were associated with better EFS, whereas chemotherapy alone did not outperform observation. In the PRR 60–90% and MPR strata, EFS curves for different postoperative strategies largely overlapped, and in MPR patients, hazard ratios were close to 1. Interaction modeling suggested that the absolute 3-year EFS benefit of immunochemotherapy peaked at intermediate PRR (≈60–80%) and diminished as PRR approached ≥90%. Conclusions: The robustness of these findings was further confirmed through a sensitivity analysis focusing on a homogeneous cohort of clinical stage II-III patients receiving adjuvant therapy. Among NSCLC patients treated with neoadjuvant systemic therapy, PRR is a strong prognostic marker and modulates the benefit of postoperative immunotherapy. These data support a response-adapted strategy, with adjuvant immunotherapy intensification in low-PRR patients and potential de-escalation or surveillance alone in MPR patients, warranting validation in prospective PRR-stratified trials.

10 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YJYuhao Jing
Yuhao Jing
ZZZhenbao Zhou
Zhenbao Zhou
MLMiao Li
Miao Li
GSGuangzhi Sun
Guangzhi Sun
XWXin Wang
Xin Wang
XLXin Li
Xin Li
Background: Randomized trials support sublobar resection for selected small peripheral lung cancers, but real-world outcomes may vary by procedure type, nodal assessment, and pathological risk. Methods: We performed a two-stage real-world analysis. Stage 1 included 22,864 patients with lung adenocarcinoma ≤3 cm from a node-assessed N0M0 SEER cohort. Stage 2 included 872 patients with node-negative lung adenocarcinoma from a multi-institutional, single-center-dominant clinicopathological cohort. The primary endpoint was disease-free survival (DFS). Results: In SEER, sublobar resection was associated with higher all-cause mortality (HR 1.31, 95% CI 1.23–1.38) and lung cancer-specific death (HR 1.38, 95% CI 1.27–1.51). Procedure-specific estimates were smaller for segmentectomy than for wedge resection and were attenuated after adjustment for examined lymph-node count. In the clinicopathological cohort, the primary postoperative model showed a higher DFS hazard with sublobar resection (HR 1.75, 95% CI 1.08–2.83), with a similar estimate after overlap weighting (HR 1.75, 95% CI 1.08–2.85). However, the association was not statistically clear after propensity-score matching (HR 1.41, 95% CI 0.76–2.63), 60-month restriction (HR 1.09, 95% CI 0.58–2.03), or restriction to a comparable-follow-up cohort (HR 1.57, 95% CI 0.88–2.78). The proportional-hazards assumption for DFS was violated, and late estimates were based on sparse risk sets and were unstable. The recurrence association was predominantly locoregional, and increasing Core-HRPF burden was associated with progressively worse prognosis. Conclusions: Real-world sublobar resection is a heterogeneous exposure. Observed outcome associations varied by procedure type, nodal assessment, analytical specification, and follow-up horizon and should not be interpreted as evidence that sublobar resection is intrinsically inferior to lobectomy.